Oncopeptides announces that the clinical development program is continuing according to plan and the company has recently initiated an additional Phase II clinical trial of Ygalo in combination with dexamethasone.
The clinical trial is conducted in patients with late stage relapsed and refractory multiple myeloma (RRMM) that are refractory to treatments with pomalidomide and/or daratumumab.
This is an important step in our strategy to develop Ygalo to become the first targeted alkylator for treating multiple myeloma patients with limited remaining treatment options” said Jakob Lindberg, CEO Oncopeptides.
The clinical study will be conducted across 15 clinics in Italy, Spain and the US, with Dana Farber Cancer Institute in Boston, MA, being the lead investigator site. The study will recruit patients that have become refractory to pomalidomide and/or daratumumab, currently the two main treatment alternatives in patients with late stage relapsed and refractory multiple myeloma.
